PhorMax gets FDA clearance and new exec
Privately held developer of low-cost CR systems PhorMax got good news and a new leader this month. The company announced Jan. 15 that the FDA had cleared its low-cost CR system, called Phormax CR. Just days earlier, the company welcomed Marvin Slosman as
Privately held developer of low-cost CR systems PhorMax got good news and a new leader this month. The company announced Jan. 15 that the FDA had cleared its low-cost CR system, called Phormax CR. Just days earlier, the company welcomed Marvin Slosman as its new president and CEO.
Slosman last served as executive vice president at Emerge Interactive, a business-to-business e-commerce market maker. While there, he guided Emerge from an early-stage startup to a successful IPO, developing and executing a strategic business plan that grew revenue from $3 million to $100 million. Along the way, the company made 11 acquisitions and partnerships. Prior to joining the B2B company, Slosman was cardiology division sales manager at Cordis, a Johnson & Johnson company. Earlier he served as vice president of business development and sales programs for GE Capital.